Skip to main content
SpringerLink
Log in

Clinical Pharmacology of Levosimendan

  • Review Article
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

Abstract

Levosimendan has been developed for the treatment of decompensated heart failure and is used intravenously when patients with heart failure require immediate initiation of drug therapy. It increases cardiac contractility and induces vasodilatation.

The pharmacokinetics of levosimendan are linear at the therapeutic dose range of 0.05–0.2 μg/kg/minute. The short half-life (about 1 hour) of the parent drug, levosimendan, enables fast onset of drug action, although the effects are long-lasting due to the active metabolite OR-1896, which has an elimination half-life of 70–80 hours in patients with heart failure (New York Heart Association functional class III-IV).

Although levosimendan is administered intravenously, it is excreted into the small intestine and reduced by intestinal bacteria to an amino phenolpyridazinone metabolite (OR-1855). This metabolite is further metabolised by acetylation to N-acetylated conjugate (OR-1896). The circulating metabolites OR-1855 and OR-1896 are formed slowly, and their maximum concentrations are seen on average 2 days after stopping a 24-hour infusion. The haemodynamic effects after levosimendan seem to be similar between fast and slow acetylators despite the fact that the enzyme N-acetyltransferase-2, which is responsible for the metabolism of OR-1855 to OR-1896, is polymorphically distributed in the population.

Levosimendan reduces peripheral vascular resistance and has direct contractility-enhancing effects on the failing left ventricle. It also improves indices of diastolic function and seems to improve the function of stunned myocardium. Despite an improvement in ventricular function, levosimendan does not increase myocardial oxygen uptake significantly. An increase in coronary blood flow and a reduction in coronary vascular resistance have been observed. Levosimendan reduces plasma brain natriuretic peptide (BNP) and N-terminal pro-BNP (NT-proBNP) levels substantially, and a decrease in plasma endothelin-1 has been observed. Levosimendan also exerts beneficial effects on proinflammatory cytokines and apoptosis mediators. The effects of a 24-hour levosimendan infusion on filling pressure, ventricular function and BNP, as well as NT-proBNP, last for at least 7 days.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Fig. 1
Table II
Fig. 2
Fig. 3
Table III
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Haikala H, Kaivola J, Nissinen E, et al. Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan. J Mol Cell Cardiol 1995; 27: 1859–66

    Article  PubMed  CAS  Google Scholar 

  2. Yokoshiki H, Katsube Y, Sunagawa M, et al. Levosimendan, a novel Ca2+ sensitizer, activates the glibenclamide-sensitive K+ channel in rat arterial myocytes. Eur J Pharmacol 1997; 333: 249–59

    Article  PubMed  CAS  Google Scholar 

  3. Szilagyi S, Pollesello P, Levijoki J, et al. The effects of levosimendan and OR-1896 on isolated hearts, myocyte-sized preparations and phosphodiesterase enzymes of the guinea pig. Eur J Pharmacol 2004; 486: 67–74

    Article  PubMed  CAS  Google Scholar 

  4. Pagel PS, Haikala H, Pentikäinen P, et al. Pharmacology of levosimendan: a new myofilament calcium sensitizer. Cardiovasc Drug Rev 1996; 14: 286–316

    Article  CAS  Google Scholar 

  5. Sandeil EP, Häyhä M, Antila S, et al. Pharmacokinetics of levosimendan in healthy volunteers and patients with congestive heart failure. J Cardiovasc Pharmacol 1995; 26 Suppl. 1: S57–62

    Google Scholar 

  6. Lilleberg J, Antila S, Karlsson M, et al. Pharmacokinetics and pharmacodynamics of simendan, a novel calcium sensitizer, in healthy volunteers. Clin Pharmacol Ther 1994; 56: 554–63

    Article  PubMed  CAS  Google Scholar 

  7. Kivikko M, Antila S, Eha J, et al. Pharmacodynamics and safety of a new calcium sensitizer, levosimendan, and its metabolites during an extended infusion in patients with severe heart failure. J Clin Pharmacol 2002; 42: 43–51

    Article  PubMed  CAS  Google Scholar 

  8. Antila S, Kivikko M, Lehtonen L, et al. Pharmacokinetics of levosimendan and its circulating metabolites in patients with heart failure after an extended continuous infusion of levosimendan. Br J Clin Pharmacol 2004; 57: 412–5

    Article  PubMed  CAS  Google Scholar 

  9. Antila S, Pesonen U, Lehtonen L, et al. Pharmacokinetics of levosimendan and its active metabolite OR-1896 in rapid and slow acetylators. Eur J Pharm Sci 2004; 23: 213–22

    Article  PubMed  CAS  Google Scholar 

  10. Kivikko M, Antila S, Eha J, et al. Pharmacokinetics of levosimendan and its metabolites during and after a 24-hour continuous infusion in patients with severe heart failure. Int J Clin Pharmacol Ther 2002; 40: 465–71

    PubMed  CAS  Google Scholar 

  11. Antila S, Järvinen A, Akkila J, et al. Studies on psychomotoric effects and pharmacokinetic interactions of the new calcium sensitizing drug levosimendan and ethanol. Arzneimittelfor-schung 1997; 47(7): 816–20

    CAS  Google Scholar 

  12. Sundberg S, Antila S, Scheinin H, et al. Integrated pharmacokinetics and pharmacodynamics of the novel calcium sensitizer levosimendan as assessed by systolic time intervals. Int J Clin Pharmacol Ther 1998; 36: 629–35

    PubMed  CAS  Google Scholar 

  13. Põder P, Eha J, Sundberg S, et al. Pharmacokinetic-pharmaco-dynamic interrelationships of intravenous and oral levosimendan in patients with severe congestive heart failure. Int J Clin Pharmacol Ther 2003; 41: 365–73

    PubMed  Google Scholar 

  14. Lehtonen LA. Levosimendan: a parenteral calcium-sensitising drug with additional vasodilatory properties. Exp Opin. Invest Drugs 2001; 10(5): 945–60

    Article  Google Scholar 

  15. Lehtonen LA, Antila S, Pentikäinen PJ. Pharmacokinetics and pharmacodynamics of intravenous inotropic agents. Clin Pharmacokinet 2004; 43: 187–203

    Article  PubMed  CAS  Google Scholar 

  16. Antila S, Huuskonen H, Nevalainen T, et al. Site dependent bioavailability and metabolism of levosimendan in dogs. Eur J Pharm Sci 1999; 9: 85–91

    Article  PubMed  CAS  Google Scholar 

  17. Jonsson EN, Antila S, McFadyen L, et al. Population pharmacokinetics of levosimendan in patients with congestive heart failure. Br J Clin Pharmacol 2003; 55: 544–51

    Article  PubMed  CAS  Google Scholar 

  18. Puttonen J, Kantele S, Kivikko M, et al. Effect of severe renal failure and haemodialysis on the pharmacokinetics of levosimendan and its metabolites. Clin Pharmacokinet 2007; 46: 235–46

    Article  PubMed  CAS  Google Scholar 

  19. Puttonen J Ruck A, Kantele S, Kivikko M, et al. Pharmacokinetics of levosimendan and its metabolites in healthy subjects and patients with hepatic impairment. J Clin Pharmacol 2006; 46: 1066

    Google Scholar 

  20. Turanlahti M, Boldt T, Palkama T, et al. Pharmacokinetics of levosimendan in pediatric patients evaluated for cardiac surgery. Pediatr Crit Care Med 2004; 5: 457–62

    Article  PubMed  Google Scholar 

  21. Antila S, Honkanen T, Lehtonen L, et al. The CYP3A4 inhibitor intraconazole does not affect the pharmacokinetics of a new calcium-sensitizing drug levosimendan. Int J Clin Pharmacol Ther 1998; 36: 446–9

    PubMed  CAS  Google Scholar 

  22. Antila S, Järvinen A, Honkanen T, et al. Pharmacokinetic and pharmacodynamic interactions between the novel calcium sensitiser levosimendan and warfarin. Eur J Clin Pharmacol 2000; 56: 705–10

    Article  PubMed  CAS  Google Scholar 

  23. Põder P, Eha J, Antila S, et al. Pharmacodynamic interactions of levosimendan and felodipine in patients with coronary heart disease. Cardiovasc Drugs Ther 2003; 17: 451–8

    Article  PubMed  Google Scholar 

  24. Sundberg S, Lehtonen L. Haemodynamic interactions between the novel calcium sensitiser levosimendan and isosorbide-5-mononitrate in healthy subjects Eur J Clin Pharmacol 2000; 55: 793–9

    Article  PubMed  CAS  Google Scholar 

  25. Lehtonen L, Sundberg S. The contractility enhancing effect of the calcium sensitiser levosimendan is not attenuated by carvedilol in healthy subjects. Eur J Clin Pharmacol 2002; 58: 449–52

    Article  PubMed  CAS  Google Scholar 

  26. Antila S, Eha J, Heinpalu M, et al. Haemodynamic interactions of a new calcium sensitizing drug levosimendan and captopril. Eur J Clin Pharmacol 1996; 49: 451–8

    Article  PubMed  CAS  Google Scholar 

  27. Lilleberg J, Sundberg S, Häyhä M, et al. Haemodynamic dose-efficacy of levosimendan in healthy volunteers. Eur J Clin Pharmacol 1994; 47: 267–74

    Article  PubMed  CAS  Google Scholar 

  28. Sundberg S, Lilleberg J, Nieminen MS, et al. Hemodynamic and neurohumoral effects of levosimendan, a new calcium sensitizer, at rest and during exercise in healthy men. Am J Cardiol 1995; 75: 1061–6

    Article  PubMed  CAS  Google Scholar 

  29. Ukkonen H, Saraste M, Akkila J, et al. Myocardial efficiency during calcium sensitization with levosimendan: a noninvasive study with positron emission tomography and echocardi-ography in healthy volunteers. Clin Pharmacol Ther 1997; 61: 596–607

    Article  PubMed  CAS  Google Scholar 

  30. Ukkonen H, Saraste M, Akkila J, et al. Myocardial efficiency during levosimendan infusion in congestive heart failure. Clin Pharmacol Ther 2000; 68: 522–31

    Article  PubMed  CAS  Google Scholar 

  31. Lilleberg J, Nieminen MS, Akkila J, et al. Effects of a new calcium sensitizer, levosimendan, on haemodynamics, coronary blood flow and myocardial substrate utilization early after coronary artery bypass grafting. Eur Heart J 1998; 19: 660–8

    Article  PubMed  CAS  Google Scholar 

  32. Michaels AD, McKeown B, Kostal M, et al. Effects of intravenous levosimendan on human coronary vasomotor regulation, left ventricular wall stress, and myocardial oxygen uptake. Circulation 2005; 111(12): 1504–9

    Article  PubMed  CAS  Google Scholar 

  33. De Luca L, Proietti P, Celotto A, et al. Levosimendan improves hemodynamics and coronary flow reserve after percutaneous coronary intervention in patients with acute myocardial infarction and left ventricular dysfunction. Am Heart J 2005; 150: 563–8

    Article  PubMed  Google Scholar 

  34. Sonntag S, Sundberg S, Lehtonen LA, et al. The calcium sensitizer levosimendan improves the function of stunned myocardium after percutaneous transluminal coronary angioplasty in acute myocardial ischemia. J Am Coll Cardiol 2004; 43: 2177–82

    Article  PubMed  CAS  Google Scholar 

  35. Givertz MM, Andreou C, Conrad CH, et al. Direct myocardial effects of levosimendan in humans with left ventricular dysfunction: alteration of force-frequency and relaxation frequency relationships. Circulation 2007; 115: 1218–24

    PubMed  CAS  Google Scholar 

  36. Parissis JT, Panou F, Farmakis D, et al. Effects of levosimendan on markers of left ventricular diastolic function and neurohormonal activation in patients with advanced heart failure. Am J Cardiol 2005; 96: 423–6

    Article  PubMed  CAS  Google Scholar 

  37. Dernellis J, Panaretou M. Effects of levosimendan on restrictive left ventricular filling in severe heart failure: a combined hemodynamic and Doppler echocardiographic study. Chest 2005; 128(4): 2633–9

    Article  PubMed  CAS  Google Scholar 

  38. Toivonen L, Viitasalo M, Sundberg S, et al. Electrophysiologic effects of a calcium sensitizer inotrope levosimendan administered intravenously in patients with normal cardiac function. J Cardiovasc Pharmacol 2000; 35: 664–9

    Article  PubMed  CAS  Google Scholar 

  39. Nieminen MS, Akkila J, Hasenfuss G, et al. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll Cardiol 2000; 36: 1903–12

    Article  PubMed  CAS  Google Scholar 

  40. Flevari P, Parissis JT, Leftheriotis D, et al. Effect of levosimendan on ventricular arrhythmias and prognostic autonomic indexes in patients with decompensated advanced heart failure secondary to ischemic or dilated cardiomyopathy. Am J Cardiol 2006; 98: 1641–5

    Article  PubMed  CAS  Google Scholar 

  41. Gegenhuber A, Mueller T, Firlinger F, et al. Time course of B-type natriuretic peptide (BNP) and N-terminal proBNP changes in patients with decompensated heart failure. Clinical Chemistry 2004; 50(2): 454–6

    Article  PubMed  CAS  Google Scholar 

  42. Adamopoulus S, Parissis JT, Iliodromitis EK, et al. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure. Am J Cardiol 2006; 98(1): 102–6

    Article  Google Scholar 

  43. Lilleberg J, Laine M, Palkama T, et al. Duration of the hemodynamic action of a 24-hour infusion of levosimendan in patients with congestive heart failure. Eur J Heart Fail 2007; 9: 75–82

    Article  PubMed  CAS  Google Scholar 

  44. McLean AS, Huang SJ, Nalos M, et al. Duration of the beneficial effects of levosimendan in decompensated heart failure as measured by echocardiographic indices and B-type natriuretic peptide. J Cardiovasc Pharmacol 2005; 46(6): 830–5

    Article  PubMed  CAS  Google Scholar 

  45. Nicklas JM, Monsur JC, Bleske BE. Effects of intravenous levosimendan on plasma neurohormone levels in patients with heart failure: relation to hemodynamic response. Am J Cardiol 1999; 83 (12 Symposium1): 12–5

    Article  Google Scholar 

  46. Parissis JF, Adamopoulos S, Antoniades C, et al. Effects of levosimendan on circulating pro-inflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure. Am J Cardiol 2004; 93: 1309–12

    Article  PubMed  CAS  Google Scholar 

  47. Kyrzopoulus S, Adamopoulus S, Parissis JT, et al. Levosimendan reduces plasma B-type natriuretic peptide and interleukin 6, and improves central hemodynamics in severe heart failure patients. Int J Cardiol 2005; 99: 409–13

    Article  Google Scholar 

  48. Avgeropoulou C, Andreadou I, Markantonis-Kyroudis S, et al. The Ca-sensitizer levosimendan improves oxidative damage, BNP and pro-inflammatory cytokine levels in patients with advanced decompensated heart failure in comparison with dobutamine. Eur J Heart Fail 2005; 7: 882–7

    Article  PubMed  CAS  Google Scholar 

  49. Ziakas DN, Chalikias GK, Hatzinikolau HI, et al. Levosimendan use reduces matrix metalloproteinase-2 in patients with de-compensated heart failure. Cardiovasc Drugs Ther 2005; 19: 399–402

    Article  Google Scholar 

  50. Slawsky MT, Colucci WS, Gottlieb SS, et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Circulation 2000; 102: 2222–7

    Article  PubMed  CAS  Google Scholar 

  51. Kivikko M, Lehtonen L, Colucci WS. Sustained hemodynamic effects of intravenous levosimendan. Circulation 2003; 107: 81–6

    Article  PubMed  CAS  Google Scholar 

  52. Follath F, Cleland JG, Just H, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 2002; 360: 196–202

    Article  PubMed  CAS  Google Scholar 

  53. Packer M, Colucci WS, Fisher L, et al. Development of a comprehensive new endpoint for the evaluation of new treatments for acute decompensated heart failure: results with levosimendan in the REVIVE-1 study [abstract]. ESC Congress; 2003 Sep 3; Vienna

  54. Garratt C, Packer M, Colucci W, et al. Development of a comprehensive new endpoint in the evaluation for acute de-compensated heart failure: results with levosimendan in the REVIVE 1 study [abstract]. 24th International Symposium on Intensive Care & Emergency Medicine; 2004 Mar 30–Apr 2; Brussels

    Google Scholar 

  55. Packer M. REVIVE II: multicenter placebo-controlled trial of levosimendan on clinical status in acutely decompensated heart failure. Late Breaking Clinical Trials II Session, American Heart Association Scientific Sessions 2005; 2005 Nov 13–16; Dallas (TX)

  56. Cleland JG, Freemantle N, Coletta AP, et al. Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE. Eur J Heart Fail 2006; 8: 105–10

    Article  PubMed  CAS  Google Scholar 

  57. Moiseyev VS, Põder P, Andrejevs N, et al. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction: a randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J 2002; 18: 1422–32

    Article  Google Scholar 

  58. Zairis MN, Apostolatos C, Anastasiadis P, et al. The effect of a calcium sensitizer or an inotrope or none in chronic low output decompensated heart failure: results from the Calcium Sensitizer or Inotrope or None in Low Output Heart Failure Study (CASINO) [abstract]. Annual Scientific Sessions of the American College of Cardiology; 2004 Mar 7–10; New Orleans (LA)

    Google Scholar 

  59. Mebazaa A, Nieminen MS, Packer M, et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA 2007; 297(17): 1883–91

    Article  PubMed  CAS  Google Scholar 

  60. Lehtonen L. Levosimendan: a promising agent for the treatment of hospitalized patients with decompensated heart failure. Curr Cardiol Rep 2000; 2: 233–43

    Article  PubMed  CAS  Google Scholar 

  61. Singh BN, Lilleberg J, Sandeil EP, et al. Effects of levosimendan on cardiac arrhythmia: electrophysiologic and ambulatory electrocardiographic findings in phase II and phase IIII clinical studies in cardiac failure. Am J Cardiol 1999; 83 Suppl. 12B: 16–20

    Article  CAS  Google Scholar 

  62. Lilleberg J, Ylönen V, Lehtonen L, et al. The calcium sensitizer levosimendan and cardiac arrhythmias: an analysis of the safety database of heart failure treatment studies. Scand Cardiovasc J 2004; 38: 80–4

    Article  PubMed  CAS  Google Scholar 

  63. Harjola V-P, Peuhkurinen K, Nieminen MS, et al. Oral levosimendan improves cardiac function and hemodynamics in patients with severe congestive heart failure. Am J Cardiol 1999; 83 Suppl. 12B: 4–8

    Article  CAS  Google Scholar 

  64. Põder P, Eha J, Sundberg S, et al. Pharmacodynamics and pharmacokinetics of oral levosimendan and its metabolites in patients with severe congestive heart failure: a dosing interval study. J Clin Pharmacol 2004; 44: 1143–50

    Article  PubMed  Google Scholar 

  65. Lechner E, Moosbauer W, Pinter M, et al. Use of levosimendan, a new inodilator, for postoperative myocardial stunning in a premature neonate. Pediatr Crit Care Med 2007; 8(1): 61–3

    Article  PubMed  Google Scholar 

  66. De Hert SG, Lorsomradee S, Cromheecke S, et al. The effects of levosimendan in cardiac surgery patients with poor left ventricular function. Anesth Analg 2007; 104(4): 766–73

    Article  PubMed  Google Scholar 

  67. Iriz E, Erer D, Unal Y, et al. Successful use of levosimendan in a patient during cardiopulmonary bypass. J Card Surg 2007; 22(2): 153–6

    Article  PubMed  Google Scholar 

  68. Akgul A, Mavioglu L, Katircioglu SF, et al. Levosimendan for weaning from cardiopulmonary bypass after coronary artery bypass grafting. Heart Lung Circ 2006; 15(5): 320–4

    Article  PubMed  CAS  Google Scholar 

  69. Tritapepe L, De Santis V, Vitale D, et al. Preconditioning effects of levosimendan in coronary artery bypass grafting a pilot study. Br J Anaesth 2006; 96(6): 694–700

    Article  PubMed  CAS  Google Scholar 

  70. Benezet-Mazuecos J, de la Hera J. Peripartum cardiomyopathy: a new successful setting for levosimendan. Int J Cardiol. Epub 2007 Feb 23

  71. Krumnikl JJ. Beneficial outcome after prostaglandin-induced post-partum cardiac arrest using levosimendan and extracorporeal membrane oxygenation. Acta Anaesthesiol Scand 2006; 50(6): 768–70

    Article  PubMed  CAS  Google Scholar 

  72. Nguyen H, McKeown B. Levosimendan for post-partum cardiomyopathy. Crit Care Resusc 2005; 7(2): 107–10

    PubMed  CAS  Google Scholar 

  73. Morelli A, Teboul J-L, Maggiore SM, et al. Effects of levosimendan on right ventricular afterload in patients with acute respiratory distress syndrome: a pilot study. Crit Care Med 2006; 34(9): 2287–93

    Article  PubMed  CAS  Google Scholar 

  74. Rivera J, Romero KA, Gonzalez-Chon O, et al. Severe stunned myocardium after lightning strike. Crit Care Med 2007; 35(1): 280–5

    Article  PubMed  Google Scholar 

  75. Beiras-Fernandez A. Levosimendan treatment after primary organ failure in heart transplantation: a direct way to recovery? Transplantation 2006 27; 82(8): 1101–3

    Article  PubMed  CAS  Google Scholar 

  76. Petäjä LM, Sipponen T, Hämmäinen PJ, et al. Levosimendan reversing low output syndrome after heart transplantation. Ann Thorac Surg 2006; 82(4): 1529–31

    Article  PubMed  Google Scholar 

  77. Schulze-Neick I, Luther YC, Ewert P, et al. End-stage heart failure with pulmonary hypertension: levosimendan to evaluate for heart transplantation alone versus combined heart-lung transplantation. Transplantation 2004; 78(8): 1237–8

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

Dr Stig Sundberg is an employee of Orion Pharma, and Drs Saila Antila and Lasse A. Lehtonen are former employees of Orion Pharma. No sources of funding were used to assist in the preparation of this review.

Author information

Authors and Affiliations

  1. National Agency for Medicines, PO Box 55, 00301, Helsinki, Finland

    Saila Antila

  2. Orion Pharma, Espoo, Finland

    Stig Sundberg

  3. Helsinki University Central Hospital, Helsinki, Finland

    Lasse A. Lehtonen

Authors
  1. Saila Antila
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stig Sundberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lasse A. Lehtonen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Saila Antila.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Antila, S., Sundberg, S. & Lehtonen, L.A. Clinical Pharmacology of Levosimendan. Clin Pharmacokinet 46, 535–552 (2007). https://doi.org/10.2165/00003088-200746070-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003088-200746070-00001

Keywords

Search

Navigation